Mint Venture Partners

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

Medinno is a South Korean biotechnology company based in Suwon that focuses on the research and development of neural stem cell–based therapies derived from adult brain tissue for degenerative neurological diseases. It develops cell therapeutics for brain disorders, with applications including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, severe intraventricular hemorrhages, stroke, and Alzheimer's disease.

Aimedbio develops therapeutic systems and medicines for serious brain diseases, including neuro-oncological and degenerative conditions, aiming to improve quality of life for patients with refractory brain diseases.

Founded in 2016, Humanscape specializes in blockchain-based health data platforms. It collects comprehensive patient health data, including genotype, clinical, and phenotype information, to facilitate drug discovery and improve treatments for intractable and rare diseases.

SanaHeal develops bioadhesive medical technologies designed for rapid and strong adhesion to wet and irregular tissue surfaces. Their platform features nature-inspired adhesives modeled after barnacles and spider webs, providing instant drying and secure attachment in moist environments.

Activ Surgical is a Boston-based digital surgery company developing a surgical imaging and software platform that uses computer vision, artificial intelligence, analytics, and machine learning to assist surgeons in complex procedures, enhance intraoperative decision-making, improve efficiency and accuracy, and reduce unintended complications. The platform supports augmented reality-based guidance and AI-driven surgery, and its robotic initiatives include the Smart Tissue Autonomous Robot, a system designed to automate aspects of tissue manipulation during surgery.

BeauBrain Healthcare specializes in early intervention for Alzheimer's disease. It offers a predictive analysis platform that identifies disease-specific biomarkers like Amyloid Beta and Tau, enabling early detection. Additionally, it provides a personalized cognitive training platform (DTx) to help manage the condition proactively.

SeaWith is a biotechnology company creating meat alternatives from seaweed, including cell-cultured steak and plant-based substitutes designed to mimic meat texture and flavor. It develops its own culture media from microalgae, aiming to reduce production costs by leveraging the abundance of algae. The company focuses on nutrition and sustainability, providing healthier protein options for consumers seeking alternatives to traditional meat.

Organoid Sciences is a biotechnology company founded in 2018 and located in Seongnam-si, South Korea. The company specializes in developing organoid-based therapies using its proprietary Keo cannabinoid technology to address various incurable diseases. In addition to drug development, Organoid Sciences provides drug screening services and focuses on regenerative medicine, aiming to advance treatment options through innovative approaches.

Sonic Incytes Medical Corp develops handheld ultrasound solutions for point-of-care assessment and monitoring of chronic liver diseases. It uses quantitative ultrasound and elastography with artificial intelligence to provide deeper measurements, larger tissue samples, and single-probe operation without recalibrations, enabling guidance for diagnostics and procedures. The devices assess liver stiffness, attenuation, and fat fraction to support diagnosis and management of liver health. The company was incorporated in 2012 and is based in Vancouver, Canada.

Key Proteo develops innovative peptide screening technology for newborns, aiming to enhance current screening programs and enable early intervention for genetic disorders. It specializes in multiplex analysis of extremely low-abundance proteins from dried blood spots using mass spectrometry.

GenoTwin is a company dedicated to integrating genomics into public health to tackle infectious disease challenges. It offers an innovative genomics platform that leverages advanced technologies in genomics, artificial intelligence, and computational biology. The platform supports clinicians, public health officials, and researchers in four primary areas: pathogen detection, pathogen surveillance, immune and resistance assessment, and precision treatment. By employing genome big data analysis, GenoTwin enables early identification and control of emerging pathogens, ultimately aiming to reduce mortality rates, enhance yield in livestock operations, and improve the effectiveness of targeted treatments in both infectious diseases and cancer.

Charco Neurotech is a medical technology company that develops non-invasive wearable devices for people with Parkinson's disease. The devices modulate sensory dysfunction to improve movement speed and help users maintain daily activities and a normal life.

Activ Surgical is a Boston-based digital surgery company developing a surgical imaging and software platform that uses computer vision, artificial intelligence, analytics, and machine learning to assist surgeons in complex procedures, enhance intraoperative decision-making, improve efficiency and accuracy, and reduce unintended complications. The platform supports augmented reality-based guidance and AI-driven surgery, and its robotic initiatives include the Smart Tissue Autonomous Robot, a system designed to automate aspects of tissue manipulation during surgery.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Mezoo is a medical device manufacturing company focused on developing innovative biomedical sensor technology aimed at enhancing human health through accurate diagnoses. The company specializes in creating a small, patch-type electrocardiogram that adheres to the chest of the test subject. This device enables real-time monitoring of cardiac activity, allowing physicians to effectively manage and prevent heart disease in patients. Through its advanced technology, Mezoo contributes to improving health outcomes and advancing the field of medical diagnostics.

NEXTON is an indoor vertical farming company based in Seoul, South Korea, established in 2017. The company specializes in the cultivation of agricultural products, focusing on hydroponically grown vegetables and herbs, including leafy greens and Korean strawberries. NEXTON operates its farm under conditions that maintain natural temperatures between 10-20°C year-round, utilizing photosynthetically-active LED lighting and a fully-recycled, chemical-free nutrient water system. This sustainable approach allows NEXTON to produce its crops without the use of pesticides or herbicides. In addition to vegetables, the company also cultivates pharmaceutical plants and ingredients for cosmetics, emphasizing a commitment to innovative and environmentally friendly agricultural practices.

Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.